Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex

Jinjie Zhang¹
Qiang Peng¹
Sanjun Shi¹
Qiang Zhang²
Xun Sun¹
Tao Gong¹
Zhirong Zhang¹

¹Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People's Republic of China; ²State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Peking, People's Republic of China

Background: As a poorly water-soluble drug, the oral application of morin is limited by its low oral bioavailability. In this study, a new self-nanoemulsifying drug delivery system (SNEDDS), based on the phospholipid complex technique, was developed to improve the oral bioavailability of morin.

Methods: Morin-phospholipid complex (MPC) was prepared by a solvent evaporation method and characterized by infrared spectroscopy and X-ray diffraction. After formation of MPC, it was found that the liposolubility of morin was significantly increased, as verified through solubility studies. An orthogonal design was employed to screen the blank SNEDDS, using emulsifying rate and particle size as evaluation indices. Ternary phase diagrams were then constructed to investigate the effects of drug loading on the self-emulsifying performance of the optimized blank SNEDDS. Subsequently, in vivo pharmacokinetic parameters of the morin-phospholipid complex self-nanoemulsifying drug delivery system (MPC-SNEDDS) were investigated in Wistar rats (200 mg/kg of morin by oral administration).

Results: The optimum formulation was composed of Labrafil® M 1944 CS, Cremophor® RH 40, and Transcutol® P (3:5:3, w/w), which gave a mean particle size of approximately 140 nm. Oral delivery of the MPC-SNEDDS exhibited a significantly greater Cmax (28.60 µg/mL) than the morin suspension (5.53 µg/mL) or MPC suspension (23.74 µg/mL) (all P, 0.05). Tmax was prolonged from 0.48 to 0.77 hours and to 1 hour for MPC and MPC-SNEDDS, respectively. In addition, the relative oral bioavailability of morin formulated in the MPC-SNEDDS was 6.23-fold higher than that of the morin suspension, and was significantly higher than that of the MPC suspension (P < 0.05).

Conclusion: The study demonstrated that a SNEDDS combined with the phospholipid complex technique was a promising strategy to enhance the oral bioavailability of morin.

Keywords: morin, phospholipid complex, self-nanoemulsifying drug delivery system, oral bioavailability

Introduction
Morin (3,5,7,2',4'-pentahydroxyflavone) is one of the flavonols that has been identified in fruits, vegetables, tea, and many medicinal herbs from Asia.¹ It has been reported to possess anti-inflammatory, anticancer, antioxidant, antihypertensive, and anticlastogenic activities.²⁻⁶ It has also been found to have an inhibitory effect on xanthine oxidase.⁷ In addition, in a toxicity study of dietary administered morin in rats, no mortality or abnormal clinical signs were shown.⁸
However, available pharmacokinetic data in both humans and rats are scarce at present. A previous study compared the pharmacokinetics between morin and quercetin after oral administration but failed to consider the absolute bioavailability of morin. As a poorly water-soluble drug, the absolute bioavailability of morin after a single oral dose is very low (<1%), as determined in the present study. To the best of the authors’ knowledge, low oral bioavailability may result in decreased efficacy when therapeutic plasma levels are not achieved, or may result in unanticipated toxicity at a high dose of morin. However, to date, few studies have focused on the applicable formulation of morin through oral administration. Most studies have used a simple morin aqueous solution via parenteral route to obtain the targeted pharmacological effect. Parenteral administration offers the best absorption but has obvious disadvantages, such as low patient compliance, safety considerations, and high medication costs. Thus, there is a pressing need to develop a new oral dosage form of morin with improved bioavailability and, furthermore, to obtain successful therapeutic effects at a decreased oral dose.

Various formulation techniques have been developed to improve the bioavailability of poorly water-soluble drugs, such as solid dispersion, cyclodextrins, emulsions, liposomes, and nanoparticles. Among these methods, much attention has recently been focused on self-nanoemulsifying drug delivery systems (SNEDDSs) to improve the oral bioavailability of poorly soluble drugs. For SNEDDSs, isotropic mixtures of oils and surfactants are used to form fine oil-in-water nanoemulsions when exposed to aqueous media, such as gastrointestinal fluids under mild agitation with droplet size less than 200 nm. Drug delivery advantages offered by SNEDDSs include presenting and maintaining the drug in a dissolved rate or in small droplets of oil; protection against enzymatic hydrolysis; the potential for enhanced absorption afforded by surfactant-induced permeability changes; and the inhibitory effect on P-glycoprotein (P-gp) activities. This renders the SNEDDS as a good candidate for oral delivery of morin in an attempt to solve its bioavailability problem.

Previous studies have demonstrated that phospholipid complexes can improve the liposolubility and the therapeutic efficacy of certain drugs with poor oral bioavailability. In this study, a phospholipid complex was prepared to improve the liposolubility of morin and facilitate the incorporation of morin into a SNEDDS.

Thus, the purpose of this study was to develop a novel SNEDDS based on the phospholipid complex technique to enhance the oral bioavailability of morin. This is the first time, to the authors’ knowledge, that an oral formulation of morin was developed to address its bioavailability problem. It is hoped that this study not only offers a good example of enhancing the oral bioavailability of poorly water soluble drugs by the combined use of phospholipid complex and a SNEDDS, but also provides a promising oral formulation of morin for clinical application.

**Materials and methods**

**Materials**

Morin hydrate was purchased from Sigma–Aldrich® (Sigma Chemical, St Louis, MO). Polyoxyyl 40 hydrogenated castor oil (Cremophor® RH 40), and polyoxyyl 35 castor oil (Cremophor® EL) were donated by BASF (Ludwigshafen, Germany). Oleoyl macrogolglycerides (Labrafilm M 1944 CS), propylene glycol laurate (Luuroglycol™ FCC), propylene glycol monolaurate (Lauroglycol™ 90), and diethylene glycol monoethyl ether (Transcutol® P) were kindly supplied by Gattefossé China Trading Company (Shanghai, People’s Republic of China). Acetonitrile of high performance liquid chromatography (HPLC) grade was purchased from SK Chemicals (Seoul, South Korea). Soya phospholipid was obtained from Lipoid (Ludwigshafen, Germany). Benzoic acid and 1,2-propylene glycol were purchased from Ruijinte Chemical Co, Ltd (Tianjin, China). Tetrahydrofuran was purchased from Bioway America (Marlton, NJ). Carboxymethyl cellulose sodium, hydrochloric acid, polyoxyethylene sorbitan monooleate (Tween® 80), ethanol, and phosphoric acid were obtained from Kernel Chemical Reagent Co, Ltd (Tianjin, China). All other chemicals were of analytical reagent grade.

**Preparation of morin-phospholipid complex**

The morin-phospholipid complex (MPC) was prepared with morin and phospholipid at a mass ratio of 1:1.5. Required amounts of morin and phospholipids were placed in a 100-mL round bottom flask, and 30 mL tetrahydrofuran was added. The mixture was then stirred with a magnetic agitator (Yuhua Instrument Co, Ltd, Gongyi, China) at 40°C for 2 hours. Afterwards, a vacuum rotary evaporator (Büchi Rotavapor® R-3; Büchi, Switzerland) was used to evaporate tetrahydrofuran, and the residue was dried under vacuum for 24 hours. The resultant MPC was transferred into a glass bottle and stored at room temperature.
Characterization of MPC

MPC was verified by Fourier transform infrared spectrophotometry (FT-IR Spectrometer IFS-55; Bruker, Fällanden, Switzerland) and X-ray diffractometry (D/max-r A; Rigaku Denki, Tokyo, Japan). The infrared spectra of morin, MPC, and physical mixture of morin and phospholipids were obtained by the KBr method. The X-ray diffractogram was scanned with the diffraction angle increasing from 0° to 60°, 2θ angle, with a step angle of 0.02° and a count time of 0.40 seconds.

Determination of morin content in MPC

The content of morin in the complex was determined by HPLC method, established according to a previous study with some modifications.9 The analysis was performed on a Waters® 2690 HPLC system equipped with a Waters 996 Photodiode Array Detector (Waters, Milford, MA). A Zorbax SB-C18 (Agilent Technologies, Santa Clara, CA) analytical column (150 mm × 4.6 mm, 5 µm) was used with a mobile phase consisting of acetonitrile and 0.5% phosphoric acid (24:76, v/v) by a flow rate of 1.0 mL/min. Detection wavelength was 252 nm, and the injection volume was 100 µL.

Studies showed that the precision, accuracy, and recovery of this HPLC method all met the measurement requirements. The linear standard curve (r = 0.9999) was used to determine the concentration of morin. All measurements were done in triplicate.

Solubility studies

Solubility studies were carried out to verify whether the liposolubility of morin was improved after formation of MPC. Excess amounts of morin, MPC, and the physical mixture of morin and phospholipid were added to 1 mL of water or n-octanol in sealed glass containers. The samples were kept at 25°C with constant shaking for 48 hours and then centrifuged at 5064 × g for 10 minutes using a table-top, high-speed centrifuge (TGL-16G; Xingke Scientific Instruments Co, Ltd, Hunan, China). Afterward, supernatants were removed and suitably diluted with methanol. The concentration of morin was determined by the HPLC method mentioned above. Each experiment was run in triplicate. Similarly, the solubilities of morin and MPC in three different oils (Labrafil M 1944 CS, Lauroglycol FCC, and Lauroglycol 90) were determined.

Formulation optimization of a blank SNEDDS

The blank SNEDDS formulation was screened by the orthogonal design using Labrafil M 1944 CS, Lauroglycol 90, and Lauroglycol FCC as oil phase; Cremophor EL, Cremophor RH 40, and Tween 80 as surfactants; and Transcutol P and 1,2-propylene glycol as cosurfactants. Eighteen different combinations were obtained, and nine experiments were then performed for each combination. Mixtures of oil, surfactants, and cosurfactants at prefixed ratios were placed in tubes and vortexed vigorously. After that, certain amounts of the mixtures were added to distilled water (v/v, 1:100). The mean particle size of the samples was determined by a photon correlation spectroscope (Malvern Zetasizer Nano ZS90, Malvern Instruments Ltd, Worcestershire, UK). All measurements were done in triplicate. The system composed of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P was further studied using the particle size and emulsification rate as indices.

Construction of ternary phase diagram

The self-emulsifying region of the selected system with different drug loading was identified from ternary phase diagrams. A series of self-emulsifying systems with varying concentrations of Labrafil M 1944 CS (5%–40%, v/v), Cremophor RH 40 (30%–70%, v/v), Transcutol P (0%–40%, v/v), and morin (1%–15%, w/w) was prepared. The samples were then vortexed and sonicated until oily liquid mixtures were obtained. Each sample was then added dropwise into distilled water (v/v, 1:100). The self-emulsifying performance of the generated samples was visually observed. Samples that showed drug precipitation or cracking were rejected. Samples that could easily spread in water and form a fine emulsion were judged as “good.” Samples were labeled as “bad” when there was poor or no emulsion formation with immediate coalescence of oil droplets when stirring was stopped.22 Phase diagrams were plotted using the above criteria. Finally, the formulation composed of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P (3:5:3) with a drug loading of 10% (w/w) was selected as the best one of its kind.

Characterization of MPC-SNEDDS

The droplet size and polydispersity index of the optimized morin-phospholipid complex-SNEDDS (MPC-SNEDDS) after dilution with distilled water (1:100, v/v) were determined. Morphological features of the MPC-SNEDDS were observed by transmission electron microscope (TEM; Hitachi H-600; Hitachi Co, Tokyo, Japan). The sample was diluted with distilled water at a ratio of 1:100 and mixed by gentle shaking. One drop of the sample was then placed on copper grids, and any excess was drawn off with filter paper.
The sample was negatively stained by 1% phosphomolybdic acid and then subjected to TEM observation.

**Pharmacokinetic studies in rats**

Animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Sichuan University (Sichuan, China). Male Wistar rats (200–250 g) were provided by the Laboratory Animal Center of Sichuan University. Rats were randomly divided into four groups (n = 5) and fasted for 12 hours before administration of doses. One group was given intravenous morin saline solution (1 mg/kg). The other three groups were given morin suspension, MPC suspension, or the MPC-SNEDDS at 200 mg/kg by gavage. Morin suspension and MPC suspension were prepared by dispersing morin and MPC in 5% sodium carboxymethyl cellulose solution, respectively.

Blood (400 µL) was collected via tail vein into heparinized centrifuge tubes at prefixed time points after administration of these four dosage forms. Plasma was separated from whole blood by centrifugation (1296 × g, 5 minutes) and stored at 4°C prior to analysis.

Rat plasma (100 µL) was pipetted into a centrifuge tube, and then equal amounts of internal standard solution containing benzoic acid in methanol, methanol, and 25% hydrochloric acid were added sequentially. The resultant mixture was vortexed for 5 minutes, hydrolyzed in 50°C water bath for 0.5 hours, vortexed again for 1 minute, and then centrifuged (12544 × g, 15 minutes). The supernatant (100 µL) was injected directly into the HPLC column.

Using the HPLC condition mentioned above, the standard curve of morin concentration in plasma was established and showed good linearity (r = 0.9996) in the range of 0.48–48 µg/mL. The standard curve equation of morin in serum was Y = 0.2082X–0.0704 (Y stands for the concentration of morin, X stands for the peak area ratio of morin to internal standard). The recovery rates of morin from high, middle, and low concentration ranges were 97.8% ± 0.012%, 95.1% ± 0.033%, and 91.2% ± 0.047%, respectively. The interday relative standard deviations were 2.18%, 2.60%, and 2.27% respectively; and the intraday relative standard deviations were 3.40%, 3.53%, and 5.10%, respectively.

This method was then applied to the pharmacokinetic studies. The pharmacokinetic data were processed by DAS 2.0 software (Mathematical Pharmacology Professional Committee of China) to calculate the pharmacokinetic parameters. The absolute bioavailability (Fₐ) and relative bioavailability (Fᵣ) were calculated according to the following equations:

\[
F_a(\%) = \frac{AUC_{test}}{AUC_{iv}}
\]

\[
F_r(\%) = \frac{AUC_{test}}{AUC_{reference}}
\]

AUC is the area under the plasma concentration-time curve from time 0 to the last sampling time for both equations.

**Statistical analysis**

Student’s t test was used for statistical comparisons between the pharmacokinetic data of these three groups. A value of \( P < 0.05 \) was considered statistically significant.

**Results and discussion**

**Characterization of MPC**

The formation of MPC was confirmed by infrared spectra and X-ray diffraction. The infrared spectra of morin, phospholipid, MPC, and the physical mixture are shown in Figure 1.
in Figure 1. There were significant differences between the spectrum of MPC (Figure 1C) and spectrum of the physical mixture (Figure 1D). The characteristic absorption peak of morin at 1625 cm$^{-1}$ ($\nu_{C=O}$) was easily found in the spectrum of physical mixture. However, the absorption peak of morin had shifted up to 1613 cm$^{-1}$ ($\nu_{C=O}$) in the MPC spectrum (Figure 1C), indicating interactions between morin and phospholipids. On the other hand, the characteristic absorption peak of phospholipid was found to be at 1734 cm$^{-1}$ ($\nu_{OH-C=O}$) in spectrums of both the complex and the physical mixture. However, the absorption strength at 1734 cm$^{-1}$ was lessened greatly by the formation of MPC, compared with that in the spectrum of phospholipid. In addition, there was no new peak observed in the MPC spectrum (Figure 1C).

Figure 2 shows the X-ray diffraction curves of morin, phospholipids, MPC, and the physical mixture. The morin powder diffraction pattern shown in Figure 2A has obvious sharp crystalline peaks. In contrast, phospholipids appeared to have an amorphous structure, as shown in Figure 2B. The crystalline structure of morin remained unchanged in the physical mixture (Figure 2D). However, as shown in Figure 2C, the crystalline peaks of MPC had disappeared, showing a structural characteristic similar to that of phospholipids. This was probably a consequence of noncovalent interactions between morin and phospholipids, such as hydrogen bonding and van der Waals forces. The morin molecule was “entrapped” in the polar head of phospholipid molecules, and thus its own crystalline characteristic was inhibited.

The content of morin in the complex determined by HPLC was 38.3% (w/w). The result was concordant with the reactant ratio of morin and phospholipids.

**Solubility studies**

The enhancement on the liposolubility of morin by the formation of MPC was investigated. As shown in Table 1, the solubility of morin in the n-octanol increased significantly after the formation of MPC. However, the hydrophilicity and lipophilicity of morin was slightly improved by the phospholipids in physical mixture. The result indicated that the phospholipids exhibited beneficial effects on the solubility of morin after the formation of MPC. Simultaneously, the solubilities of morin and MPC in different types of oils were also investigated. Table 2 shows the enhancements on the solubility of morin in three types of oils after the formation of MPC. As shown in Table 2, the solubility of MPC was significantly higher than that of morin, suggesting that the formation of MPC

![Figure 2 X-ray diffraction pattern of (A) morin; (B) phospholipids; (C) morin-phospholipid complex; and (D) physical mixture of morin and phospholipids.](https://www.dovepress.com/)

### Table 1 Solubility of morin, MPC, and the physical mixture in water and n-octanol at room temperature

<table>
<thead>
<tr>
<th>Sample</th>
<th>Solubility in water (µg/mL)</th>
<th>Solubility in n-octanol (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morin</td>
<td>18.42 ± 1.49</td>
<td>11.96 ± 6.71</td>
</tr>
<tr>
<td>MPC</td>
<td>74.43 ± 0.36</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Physical mixture</td>
<td>34.40 ± 0.01</td>
<td>13.85 ± 0.09</td>
</tr>
</tbody>
</table>

**Notes:** Reported as mean ± standard deviation; n = 3.

**Abbreviations:** MPC, morin-phospholipid complex; the mixture of phospholipids and morin, physical mixture.

### Table 2 Solubility of morin and MPC in different oils at room temperature

<table>
<thead>
<tr>
<th>Type of oil</th>
<th>Solubility (mg/mL)</th>
<th>Morin$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauroglycol™ FCC</td>
<td>20.40 ± 1.43</td>
<td>3.15 ± 0.056</td>
</tr>
<tr>
<td>Labrafil® M 1944 CS</td>
<td>27.04 ± 1.38</td>
<td>5.83 ± 0.12</td>
</tr>
<tr>
<td>Lauroglycol 90</td>
<td>325.60 ± 52.31</td>
<td>83.30 ± 2.34</td>
</tr>
</tbody>
</table>

**Notes:** Reported as mean ± standard deviation; n = 3.

**Abbreviation:** MPC, morin-phospholipid complex.
As shown in Table 4, all of the translucent nanoemulsions showed mean droplet sizes in the range of 20–100 nm. Unfortunately, all samples were turbid when Lauroglycol 90 was used as oil phase. However, translucent nanoemulsions can be formed in the case of Labrafil M 1944 CS, which probably is due to its greater hydrophilicity and surfactant-like properties.23 In recent years, many drugs have been reported to exhibit significantly higher bioavailability after administration of an a long-chain triglyceride (LCT) solution formulation than a similar medium-chain triglyceride (MCT) solution, probably because of the more effective lymphatic drug transport or more efficient solubilization in the gastrointestinal tract by the long-chain lipid digestion product.24 With LCTs, there may be a potential advantage with using Labrafil M 1944 CS as the oil phase. Transcutol P and 1,2-propylene glycol were investigated as cosurfactants for their good solubility of morin (more than 1 g/mL). The results show that Transcutol P exhibited better self-nanoemulsifying ability due to its greater fluidity and compatibility than 1,2-propylene glycol. In addition, the formulation composed of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P at a ratio of 3:5:3 was found to have the smallest particle size (28.34 ± 0.03 nm), with a narrow size distribution (0.067 ± 0.006), after dilution. Thus, the combination of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P was chosen for further study.

Table 3 Factors and levels of L\textsubscript{9} (3\textsuperscript{3}) orthogonal test

<table>
<thead>
<tr>
<th>Run</th>
<th>Oil</th>
<th>Surfactant</th>
<th>Cosurfactant</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1 (3)</td>
<td>1 (3)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>2</td>
<td>1 (3)</td>
<td>2 (4)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>3</td>
<td>1 (3)</td>
<td>3 (5)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>4</td>
<td>2 (4)</td>
<td>1 (3)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>5</td>
<td>2 (4)</td>
<td>2 (4)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>6</td>
<td>2 (4)</td>
<td>3 (5)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>7</td>
<td>3 (5)</td>
<td>1 (3)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>8</td>
<td>3 (5)</td>
<td>2 (4)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>9</td>
<td>3 (5)</td>
<td>3 (5)</td>
<td>2 (2)</td>
</tr>
</tbody>
</table>

Notes: Orthogonal experimental form of L\textsubscript{9} (3\textsuperscript{3}) was adopted to determine the ratios of oil, surfactant, and cosurfactant to be evaluated to a self-nanoemulsifying drug delivery system (SNEDDS) formulation.

could drastically facilitate the incorporation of morin into a SNEDDS. The solubility of morin in many other oils was less than 5 mg/mL, even after MPC formation (data not shown).

Development of MPC-SNEDDS

As a simple, fast, and economical method, orthogonal design was used to screen the optimum blank SNEDDS. The ratios at which the oil, surfactants, and cosurfactants were mixed with each other are shown in Table 3. The droplet sizes of the resultant translucent nanoemulsions for each combination are listed in Table 4.

Table 4 Droplet size and polydispersity index of SNEDDS formulations after dilution with distilled water at a ratio of 1:100

<table>
<thead>
<tr>
<th>System</th>
<th>Ratio</th>
<th>Particle size (nm)\textsuperscript{a}</th>
<th>Polydispersity index\textsuperscript{a}</th>
<th>Time of emulsification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labrafil\textsuperscript{®} M 1944 CS/Cremophor\textsuperscript{®} EL/Transcutol\textsuperscript{®} P</td>
<td>3:1</td>
<td>35.21 ± 0.79</td>
<td>0.111 ± 0.016</td>
<td>1 min–3 min</td>
</tr>
<tr>
<td></td>
<td>3:2</td>
<td>28.73 ± 0.61</td>
<td>0.098 ± 0.013</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>3:5:3</td>
<td>28.34 ± 0.56</td>
<td>0.067 ± 0.006</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>4:3:2</td>
<td>33.85 ± 1.21</td>
<td>0.082 ± 0.006</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>4:4:3</td>
<td>36.92 ± 1.94</td>
<td>0.222 ± 0.031</td>
<td>1 min–3 min</td>
</tr>
<tr>
<td>Labrafil M 1944 CS/Cremophor RH 40/Transcutol P</td>
<td>3:1</td>
<td>39.93 ± 0.87</td>
<td>0.099 ± 0.013</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>3:2</td>
<td>30.48 ± 0.74</td>
<td>0.141 ± 0.019</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>3:5:3</td>
<td>28.34 ± 0.03</td>
<td>0.079 ± 0.003</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>4:3:2</td>
<td>39.45 ± 1.17</td>
<td>0.093 ± 0.009</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>4:4:3</td>
<td>29.93 ± 0.92</td>
<td>0.114 ± 0.017</td>
<td>1 min–3 min</td>
</tr>
<tr>
<td></td>
<td>4:5:1</td>
<td>37.20 ± 0.63</td>
<td>0.228 ± 0.039</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>5:4:1</td>
<td>43.59 ± 1.85</td>
<td>0.101 ± 0.008</td>
<td>1 min–3 min</td>
</tr>
<tr>
<td></td>
<td>5:3:3</td>
<td>76.75 ± 2.16</td>
<td>0.243 ± 0.011</td>
<td>1 min–3 min</td>
</tr>
<tr>
<td>Lauroglycol\textsuperscript{TM} FCC/Cremophor RH 40/Transcutol P</td>
<td>3:1</td>
<td>35.69 ± 1.22</td>
<td>0.288 ± 0.039</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>3:2</td>
<td>34.38 ± 0.97</td>
<td>0.101 ± 0.020</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>3:5:3</td>
<td>32.45 ± 1.13</td>
<td>0.253 ± 0.041</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td></td>
<td>4:3:2</td>
<td>41.93 ± 1.52</td>
<td>0.088 ± 0.002</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td>Lauroglycol FCC/Tween\textsuperscript{®} 80/1, 2-propylene glycol</td>
<td>4:4:3</td>
<td>37.93 ± 2.90</td>
<td>0.228 ± 0.027</td>
<td>&lt; 1 min</td>
</tr>
<tr>
<td>Lauroglycol FCC/Cremophor EL/Transcutol P</td>
<td>3:1</td>
<td>57.17 ± 2.03</td>
<td>0.388 ± 0.046</td>
<td>&gt; 3 min</td>
</tr>
<tr>
<td>Labrafil M 1944 CS/Tween 80/Transcutol P</td>
<td>3:5:3</td>
<td>97.40 ± 4.58</td>
<td>0.267 ± 0.031</td>
<td>&lt; 1 min</td>
</tr>
</tbody>
</table>

Notes: \textsuperscript{a}Reported as mean ± standard deviation; n = 3.
The self-emulsifying performance of the selected SNEDDS with varying drug loading was accessed using ternary phase diagrams. The results show that the self-emulsification region of the formulation decreased on increased drug loading. To obtain a good balance between drug loading and efficient emulsification, the formulation composed of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P (3:5:3) with a drug loading of 10% (w/w) was selected. The ternary phase diagram of the optimized formulation is shown in Figure 3.

Characterization of MPC-SNEDDS

The prepared MPC-SNEDDS gave a mean particle size of 140.40 nm after dilution with distilled water. No precipitation of the drug was found when the sample was kept for 12 hours at 25°C. As shown in the TEM image (Figure 4), the SNEDDS prepared in the optimized formulation appears to have spherical particles after dilution.

Pharmacokinetic results

The selectivity of the HPLC method was evaluated before conduction of the pharmacokinetic study. Figure 5 illustrates the chromatography of morin. Under the HPLC...
condition, the chromatograms show that there was no endogenous peaks interfering with morin or the internal standard. In addition, morin peaks can be separated well from benzoic acid peaks without any interference. The plasma concentration of morin after intravenous administration is shown in Figure 6. Intravenous data were used to calculate the absolute bioavailability of morin after oral administration of morin suspension, MPC suspension, and the MPC-SNEDDS. The plasma concentration-time curves of morin after oral administration are shown in Figure 7. As shown, the MPC-SNEDDS formulation-treated rat group had the highest concentration of morin in the plasma among the three groups during 0–5 hours (Figure 7). The oral pharmacokinetic parameters are summarized in Table 5. It was notable that the C<sub>max</sub> of the MPC-SNEDDS (28.60 µg/mL) group was significantly higher than the morin suspension (5.53 µg/mL) and MPC suspension (23.74 µg/mL) groups. Compared with the morin suspension, Tmax was prolonged from 0.48 to 0.77 hours and 1 hour for the MPC and the MPC-SNEDDS groups, respectively. Compared to the morin suspension, the mean relative bioavailabilities of the MPC and the MPC-SNEDDS were 541.73% and 722.84%, respectively.

To the authors’ knowledge, the in vivo tests are the first to report the absolute bioavailability of morin, which was only 0.45%. It was assumed that the low oral bioavailability of morin may be caused by its low aqueous solubility (0.25 mg/mL, distilled water, 25°C), P-gp-mediated efflux, and low intestinal permeability (P<sub>app</sub> = 0.62 nm/s).<sup>25</sup> The absolute bioavailability of morin in rats was significantly increased by the MPC-SNEDDS compared to the morin and MPC suspensions. Reasons for this may include the following: (1) After oral administration, the intestinal mixing of the excipients, their digestion products, and bile components leads to the formation of mixed micelles and vesicles, thus improving the solubilization power of the gastrointestinal tract components;<sup>26</sup> (2) The presence of a

![Figure 6](image1.png)  
**Figure 6** Plasma concentration-time curve after intravenous administration of morin in Wistar rats (n = 5) at a dose of 1 mg/kg.

![Figure 7](image2.png)  
**Figure 7** Mean plasma concentration-time profiles of morin in Wistar rats (n = 5) after oral administration of morin, MPC, and MPC-SNEDDS formulation at a dose of 200 mg/kg.  
**Abbreviations:** MPC, morin-phospholipid complex; MPC-SNEDDS, morin-phospholipid complex self-nanoemulsifying drug delivery system.

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Bioavailability and pharmacokinetic parameters (mean ± standard deviation) of morin in Wistar rats after oral administration of morin, MPC, and MPC-SNEDDS at a dose of 200 mg/kg (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intravenous morin (1 mg/kg)</strong></td>
<td><strong>Oral morin</strong></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-t&lt;/sub&gt; (mg/L h)</td>
<td>11.89 ± 0.21</td>
</tr>
<tr>
<td>MRT&lt;sub&gt;T&lt;/sub&gt; (h)</td>
<td>1.33 ± 0.32</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>0.05 ± 0.00</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (µg/mL)</td>
<td>13.86 ± 3.91</td>
</tr>
<tr>
<td>F&lt;sub&gt;a&lt;/sub&gt; (%)</td>
<td>100.00</td>
</tr>
<tr>
<td>F&lt;sub&gt;r&lt;/sub&gt; (%)</td>
<td>–</td>
</tr>
</tbody>
</table>

**Notes:** *P < 0.05 compared with morin group; **P < 0.01 compared with morin group; †P < 0.05 MPC-SNEDDS group compared with MPC group; ‡P < 0.01 MPC-SNEDDS compared with MPC group.  
**Abbreviations:** F<sub>a</sub>, absolute bioavailability; MRT, mean retention time; MPC, morin-phospholipid complex; MPC-SNEDDS, morin-phospholipid complex self-nanoemulsifying drug delivery system; F<sub>r</sub>, relative bioavailability.
SNEDDS can act as an intestinal permeability enhancer, which may result in increased absorption of morin via paracellular or transcellular routes.27,28 Cremophor RH 40 and Transcutol P can inhibit the activity of the intestinal efflux pump (P-gp), and thus increase the absorption of morin in the gastrointestinal tract. Details on the potential effects of nonionic surfactants and cosurfactants on P-gp activity have also been published in other literature.29,30

The interaction between the MPC-SNEDDS formulation and the biological environment is rather complicated, and consequently, the definite absorption mechanisms and the potential toxicity of the MPC-SNEDDS requires further investigation.

**Conclusion**

In this study, a MPC-loaded SNEDDS for oral administration was successfully developed. The phospholipid complex significantly improved the liposolubility of morin. The optimum SNEDDS formulation was a mixture of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P at a ratio of 3:5:3 (w/w/w). The absolute bioavailability of morin increased about 6.2-fold after oral administration of the MPC-SNEDDS, compared with that of the morin suspension. This study represents initial efforts to develop a promising oral SNEDDS, compared with that of the morin suspension. This study represents initial efforts to develop a promising oral formulation of morin. In addition, it supports the technique of using a SNEDDS combined with the phospholipid complex technique as a promising delivery system to enhance the oral absorption of poorly water-soluble drugs.

**Acknowledgments**

This work was funded by the National Basic Research Program of China (973 program, No: 2009CB930300) and supported by the National Science and Technology Major Project of China (Grant No: 2009ZX09310-002). The authors would like to thank Rasa Hamilton (H Lee Moffitt Cancer Center, FL) for editorial assistance.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


